Image
Real-World Perspectives™

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Meeting Slides

Clinical Practice Guidelines

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.

Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services

Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy.

World Health Organization

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV resources

National Institutes of Health

Suggested Readings

Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results.

Arribas JR, Thompson M, Sax PE, et al. J Acquir Immune Defic Syndr. 2017;75(2):211-218.

Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the southern United States.

Colasanti J, Sumitani J, Mehta CC, et al. Open Forum Infect Dis. 2018;5(6):ofy104. 

Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort.

Cuzin L, Cotte L, Delpierre C, et al. PLoS One. 2019;14(9):e0222067.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association.

Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.

Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.

Ford S, Crauwels H, Han K, et al. CROI. Virtual Meeting. March 8-11, 2020. Abstract 466.

Linkage and antiretroviral therapy within 72 hours at a Federally Qualified Health Center in New Orleans.

Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.

Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.

Lagathu C, Béréziat V, Gorwood J, et al. Expert Opin Drug Saf. 2019;18(9):829-840.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Rapid initiation of antiretroviral therapy for people living with HIV.

Mateo-Urdiales A, Johnson S, Smith R, et al. Cochrane Database Syst Rev. 2019;6(6):CD012962. 

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.

Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

Ryom L, Cotter A, De Miguel R, et al. HIV Med. 2020;21(10):617-624.

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.

Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1379-1389.

Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.

Segal-Maurer S, Castagna A, Berhe M, et al.  CROI. March 6-10, 2021; Virtual Conference. Abstract 127.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination